image
Healthcare - Biotechnology - NASDAQ - US
$ 1.19
4.35 %
$ 12.7 M
Market Cap
-1.01
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 23, 2025.

The intrinsic value of one MRKR stock under the worst case scenario is HIDDEN Compared to the current market price of 1.19 USD, Marker Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 23, 2025.

The intrinsic value of one MRKR stock under the base case scenario is HIDDEN Compared to the current market price of 1.19 USD, Marker Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 23, 2025.

The intrinsic value of one MRKR stock under the best case scenario is HIDDEN Compared to the current market price of 1.19 USD, Marker Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart MRKR

image
$5.0$5.0$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.5$1.0$1.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
6.59 REVENUE
199058047.17%
(11.1) OPERATING INCOME
-76250388.81%
-10.7 M NET INCOME
23.60%
(10.9) OPERATING CASH FLOW
-66364558.65%
0 INVESTING CASH FLOW
0.00%
15 M FINANCING CASH FLOW
1256.54%
6.59 REVENUE
342212112.79%
(11.1) OPERATING INCOME
-463289613.37%
-3.84 M NET INCOME
-66.26%
(10.9) OPERATING CASH FLOW
-911092017.01%
0 INVESTING CASH FLOW
0.00%
14.9 M FINANCING CASH FLOW
875614.93%
Balance Sheet Marker Therapeutics, Inc.
image
Current Assets 22
Cash & Short-Term Investments 19.2
Receivables 2.35
Other Current Assets 484 B
Non-Current Assets 0
Long-Term Investments 0
PP&E 0
Other Non-Current Assets 0
87.15 %10.66 %Total Assets$22.0t
Current Liabilities 3.46
Accounts Payable 1.07 M
Short-Term Debt 0
Other Current Liabilities 3.46
Non-Current Liabilities 0
Long-Term Debt 0
Other Non-Current Liabilities 0
100.00 %Total Liabilities$3.5t
EFFICIENCY
Earnings Waterfall Marker Therapeutics, Inc.
image
Revenue 6.59
Cost Of Revenue 0
Gross Profit 6.59
Operating Expenses 17.7
Operating Income (11.1)
Other Expenses (11.1)
Net Income -10.7 M
8t8t6t6t4t4t2t2t00(2t)(2t)(4t)(4t)(6t)(6t)(8t)(8t)(10t)(10t)(12t)(12t)7t07t(18t)(11t)11t(11m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
-168.69% OPERATING MARGIN
-168.69%
-0.00% NET MARGIN
-0.00%
-0.00% ROE
-0.00%
-0.00% ROA
-0.00%
-60.19% ROIC
-60.19%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Marker Therapeutics, Inc.
image
00(2t)(2t)(4t)(4t)(6t)(6t)(8t)(8t)(10t)(10t)(12t)(12t)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -10.7 M
Depreciation & Amortization (11.1)
Capital Expenditures 0
Stock-Based Compensation 246 B
Change in Working Capital -425 K
Others (11.2)
Free Cash Flow (10.9)
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Marker Therapeutics, Inc.
image
MRKR has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 15
6. Ownership
Insider Ownership Marker Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
1.81 M USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a panel discussion at Canaccord Genuity's Horizons in Oncology Virtual Conference. globenewswire.com - 1 month ago
Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results Lead program investigating MT-601 in patients with refractory lymphomas, including anti-CD19 CAR-T cell therapy, demonstrated safety and efficacy in 9 patients with 78% having objective responses, including durable complete responses globenewswire.com - 1 month ago
Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference HOUSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics, will present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference. This virtual investor event will be held on February 25, 2025. globenewswire.com - 2 months ago
Marker Therapeutics Announces $16.1 Million Private Placement Strategic financing supports clinical advancement in Phase 1 APOLLO study investigating MT-601 in patients with lymphoma who relapsed after anti-CD19 CAR-T cells Strategic financing supports clinical advancement in Phase 1 APOLLO study investigating MT-601 in patients with lymphoma who relapsed after anti-CD19 CAR-T cells globenewswire.com - 4 months ago
Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma APOLLO study investigating MT-601 in patients with relapsed lymphoma: 78% of patients achieved objective response rates, with 44.4% demonstrating complete response (CR) globenewswire.com - 4 months ago
Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer HOUSTON, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that the Company has been awarded a $9.5 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to support the clinical investigation of MT-601 in patients with metastatic pancreatic cancer. globenewswire.com - 4 months ago
Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium HOUSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics, will present at the Ladenburg Thalmann & Co. Virtual Oncology Innovators & Investors Symposium. This virtual investor event will be held on December 12, 2024. globenewswire.com - 4 months ago
Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit HOUSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics, will present at the Citizens JMP Hematology and Oncology Summit. This investor event will be held virtually on December 2, 2024. globenewswire.com - 5 months ago
Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates Marker Therapeutics to receive two grants from NIH Small Business Innovation Research (SBIR) program to support clinical investigation of MT-601 in patients with lymphoma and metastatic pancreatic cancer Marker Therapeutics to receive two grants from NIH Small Business Innovation Research (SBIR) program to support clinical investigation of MT-601 in patients with lymphoma and metastatic pancreatic cancer globenewswire.com - 5 months ago
Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study globenewswire.com - 8 months ago
Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma Marker Therapeutics to receive non-dilutive funding from NIH Small Business Innovation Research Program based on preliminary clinical results and non-clinical data in lymphoma Marker Therapeutics to receive non-dilutive funding from NIH Small Business Innovation Research Program based on preliminary clinical results and non-clinical data in lymphoma globenewswire.com - 8 months ago
Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study globenewswire.com - 11 months ago
8. Profile Summary

Marker Therapeutics, Inc. MRKR

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 12.7 M
Dividend Yield 0.00%
Description Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.
Contact 3200 Southwest Freeway, Houston, TX, 77027 https://www.markertherapeutics.com
IPO Date July 16, 2002
Employees 5
Officers Mr. Edmund Cheung Vice President of Human Resources Patricia Allison Head of Clinical Operations Dr. Maria-Bernadette Madel Director of Corporate Operations & External Communications Dr. Juan F. Vera M.D. Co-Founder, Chief Executive Officer, President, Treasurer, Secretary & Director Ms. Elizabeth Donnelly Director of Administration Dr. Robert Z. Florkiewicz Sr., Ph.D. Senior Director of Molecular Biology & Virology Ms. Mary Newman Ph.D. Head of Regulatory Affairs Dr. F. Andrew Dorr M.D. Chief Medical Officer